https://www.tecartushcp.com/ 2023-12-21 monthly 1.0 https://www.tecartushcp.com/-/media/tecartushcp/splitter-hero--all.ashx?h=653&iar=0&w=718&hash=35E3D1D54372F775C93440D7C05140E0 https://www.tecartushcp.com/-/media/tecartushcp/splitter-hero--mcl.ashx?h=653&iar=0&w=717&hash=B27BA7A714BECE087375B68EA0AD38D4 https://www.tecartushcp.com/car-t-cell-therapy/acute-lymphoblastic-leukemia 2023-12-21 monthly 0.9 https://www.tecartushcp.com/-/media/tecartushcp/woman_homepage_d.ashx?h=1212&iar=0&w=1994&hash=DEC9850D01907D738673FAECD417D805 https://www.tecartushcp.com/-/media/tecartushcp/woman_homepage_m.ashx?h=501&iar=0&w=826&hash=9040E0550E76CF4CAA0D1560E23FAB7C https://www.tecartushcp.com/car-t-cell-therapy/mantle-cell-lymphoma 2023-12-21 monthly 0.9 https://www.tecartushcp.com/-/media/tecartushcp/bg--hcp-hero.ashx?h=713&iar=0&w=800&hash=30E32543DDD3C8AD95A0D850A2A73074 https://www.tecartushcp.com/-/media/tecartushcp/mobile-graph.ashx?h=576&iar=0&w=963&hash=5DD8EC5FD7CE526F2351529AA3A7DE14 https://www.tecartushcp.com/car-t-cell-therapy/acute-lymphoblastic-leukemia/request-a-rep 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/icon--form--color.ashx https://www.tecartushcp.com/car-t-cell-therapy/acute-lymphoblastic-leukemia/about-car-t 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/icon--leukapheresis-circle.ashx?iar=0&hash=6B63A43D777282395BBA76CE2E0EF824 https://www.tecartushcp.com/tecartushcp/tecartushcp.com/Content/svg/icon--arrow-right-dark-purple.svg https://www.tecartushcp.com/tecartushcp/tecartushcp.com/Content/svg/icon--arrow-down-dark-purple.svg https://www.tecartushcp.com/-/media/tecartushcp/icon--enrichment-circle.ashx?iar=0&hash=C609004349260FC6DC4481132BDA4E42 https://www.tecartushcp.com/-/media/tecartushcp/icon--activation-circle.ashx?iar=0&hash=4C487C5BF89A6793EE57816895E50916 https://www.tecartushcp.com/tecartushcp/tecartushcp.com/Content/svg/icon--arrow-wrap-dark-purple.svg https://www.tecartushcp.com/-/media/tecartushcp/icon--transduction-circle.ashx?iar=0&hash=811F7E796D9E49397CB774E265D1AAAB https://www.tecartushcp.com/-/media/tecartushcp/icon--expansion-circle.ashx?iar=0&hash=238785EEFA15EEECD57E73D955D5DBD1 https://www.tecartushcp.com/-/media/tecartushcp/icon--suspension-ircle.ashx?iar=0&hash=B2DD2088836D54BB598B703D94CBB079 https://www.tecartushcp.com/car-t-cell-therapy/mantle-cell-lymphoma/safety-profile 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/branded-table-ae-summary-d.ashx?iar=0&hash=358A4C0A8360DCDEC880B8660461EAA7 https://www.tecartushcp.com/-/media/tecartushcp/charts-website-mobile-ae-summary.ashx?iar=0&hash=28C240D9D042FDEAF4D4ECC9F9824C30 https://www.tecartushcp.com/-/media/tecartushcp/table-grades-d.ashx?iar=0&hash=62E7DD8533D13256FFFA92A62F1C2089 https://www.tecartushcp.com/-/media/tecartushcp/table-grades-m.ashx?iar=0&hash=CAB16BDF62ADF054D869CF1FE79067B4 https://www.tecartushcp.com/car-t-cell-therapy/mantle-cell-lymphoma/treatment 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/graphic--treatment-process--large.ashx?iar=0&hash=7F1D65818A2B2C70EDC10215467FA79E https://www.tecartushcp.com/-/media/tecartushcp/graphic--treatment-process--small.ashx?iar=0&hash=983358E73631CC1498C27000AB1A5D8C https://www.tecartushcp.com/car-t-cell-therapy/mantle-cell-lymphoma/request-a-rep 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/icon--form--color.ashx https://www.tecartushcp.com/car-t-cell-therapy/mantle-cell-lymphoma/design-and-manufacturing 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/image--binding-mechanism--color.ashx?iar=0&hash=D136B9A0A708D56EC3C4F00C398A5DED https://www.tecartushcp.com/-/media/tecartushcp/image--binding-mechanism--color-m.ashx?iar=0&hash=B67F798DEB6E474373519FA9DAACD3E5 https://www.tecartushcp.com/-/media/tecartushcp/predictabilityreliabilityflexibilityd.ashx?iar=0&hash=8D399C306B491BB8DB433B7441849CCE https://www.tecartushcp.com/-/media/tecartushcp/predictabilityreliabilityflexibilitym.ashx?iar=0&hash=41403AA282E22BA533641C2CE93E3AA6 https://www.tecartushcp.com/car-t-cell-therapy/about-mantle-cell-lymphoma 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/image--mcl-b-cells--gray-large.ashx?iar=0&hash=9FBA4FCA70D78565FC9D0265624EEE15 https://www.tecartushcp.com/-/media/tecartushcp/image--mcl-b-cells--gray-small.ashx?iar=0&hash=E6F97760AACDB7A44324E7586D24DAF5 https://www.tecartushcp.com/-/media/tecartushcp/icon--mcl-man-line.ashx?h=613&iar=0&w=792&hash=1915E0837FF8F5D953AA9454D386B90F https://www.tecartushcp.com/-/media/tecartushcp/icon--mcl-man-line-mobile.ashx?h=1195&iar=0&w=279&hash=E48051A51C5BCB0042B6BCBBCCC18638 https://www.tecartushcp.com/-/media/tecartushcp/copy-of-icon--hic-stains--gray--mcl.ashx?iar=0&hash=2D194A491C7802FD1D8754E7DDEE2FEA https://www.tecartushcp.com/-/media/tecartushcp/copy-of-icon--genetic-testing--gray--mcl.ashx?iar=0&hash=662405D1BF16CA2B1B06CD45E30433B8 https://www.tecartushcp.com/-/media/tecartushcp/copy-of-icon--microscope--gray--mcl.ashx?iar=0&hash=07CD82BCC8120C73189B21D725550C0D https://www.tecartushcp.com/-/media/tecartushcp/icon--other-testing--gray.ashx?iar=0&hash=D43B34D7C5BCD35742ADA44EDEC3D733 https://www.tecartushcp.com/-/media/tecartushcp/icon--alert-triangle--tan.ashx?iar=0&hash=F38B09ACF696D10FEF3443EBAAEA228A https://www.tecartushcp.com/car-t-cell-therapy/mantle-cell-lymphoma/about-car-t 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/6stepsprocessd.ashx?iar=0&hash=3D6365E05D35B3F832424DD44DF4DD4F https://www.tecartushcp.com/-/media/tecartushcp/6stepsprocessm.ashx?iar=0&hash=FE5C59EF49BBFB3070F910180305FE61 https://www.tecartushcp.com/car-t-cell-therapy/mantle-cell-lymphoma/response 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/chart--response-orr--large.ashx?iar=0&hash=31E4109C56E504D2272C6C807D51B082 https://www.tecartushcp.com/-/media/tecartushcp/chart--response-orr--small.ashx?iar=0&hash=92DEC53DAEDCBA43DAA6DD644C7ACA4A https://www.tecartushcp.com/-/media/tecartushcp/chart--response-dor--large.ashx?iar=0&hash=9B4FC7D952F1782AED3A172D4772E1E1 https://www.tecartushcp.com/-/media/tecartushcp/chart--response-dor--small.ashx?iar=0&hash=B5172126CE62006687D834DC0A74ACC6 https://www.tecartushcp.com/car-t-cell-therapy/mantle-cell-lymphoma/additional-efficacy-data 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/os-3-year-graph-d.ashx?iar=0&hash=1F99A71E68DDE0BCB6EEF28D4F3E1A2D https://www.tecartushcp.com/-/media/tecartushcp/os-3-year-graph-m.ashx?iar=0&hash=692FDB16A91203B569523CD2B1145CF2 https://www.tecartushcp.com/-/media/tecartushcp/pfs-3-year-d.ashx?iar=0&hash=BDCC7BD073A5768EC01C4500E4CA12A7 https://www.tecartushcp.com/-/media/tecartushcp/48-progression.ashx?iar=0&hash=08F1082F3BCCB954663918CEA62B1912 https://www.tecartushcp.com/car-t-cell-therapy/about-acute-lymphoblastic-leukemia 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/about-all--people-icons.png?iar=0&hash=BAC18445AFAECA209D07DD848E0BDEB9 https://www.tecartushcp.com/-/media/tecartushcp/about-all--people-icons-mobile.png?iar=0&hash=53A6D897214B6358D083E700FFBB82BF https://www.tecartushcp.com/-/media/tecartushcp/image--all-b-cell--gray-large.ashx?iar=0&hash=1C9BF5E3E6050004458886850B916B8D https://www.tecartushcp.com/-/media/tecartushcp/image--all-b-cell--gray-small.ashx?iar=0&hash=9EFD54B60863BD2D2DBE1436E8899D20 https://www.tecartushcp.com/-/media/tecartushcp/icon--all-man-line.ashx?iar=0&hash=CF09D7B90B2C015E0D025D0BB8940524 https://www.tecartushcp.com/-/media/tecartushcp/icon--all-man-line-mobile.ashx?iar=0&hash=E297E9EE021FEBBCCBAE0EBA00EED07B https://www.tecartushcp.com/-/media/tecartushcp/icon--hic-stains--gray.ashx?iar=0&hash=F12F1139AE4E9CE83FA8167D3D413878 https://www.tecartushcp.com/-/media/tecartushcp/icon--genetic-testing--gray.ashx?iar=0&hash=8E42ECDABB93F1FD081CBE4EBA51B6B8 https://www.tecartushcp.com/-/media/tecartushcp/icon--microscope--gray.ashx?iar=0&hash=EBA1509AEB415122416E2A2AB8AD1FBB https://www.tecartushcp.com/-/media/tecartushcp/image--all-percentage--large.ashx?iar=0&hash=F48840AE29AAC6C1B97B759FE2B5E54C https://www.tecartushcp.com/-/media/tecartushcp/image--all-percentage--small.ashx?iar=0&hash=02B5D599752C39DA113A7126A0C6DC00 https://www.tecartushcp.com/-/media/tecartushcp/icon--all-factor--gray-calendar.ashx?iar=0&hash=4A6B586BF4C352ED2C9E0FE7B3622CFC https://www.tecartushcp.com/-/media/tecartushcp/icon--all-factor--gray-calendar-mobile.ashx?iar=0&hash=61843D98A724EA26A75BEBA8F6772225 https://www.tecartushcp.com/-/media/tecartushcp/icon--all-factor--gray-dna.ashx?iar=0&hash=0B519E29226608A6EB2C058D97191A18 https://www.tecartushcp.com/-/media/tecartushcp/icon--all-factor--gray-dna-mobile.ashx?iar=0&hash=7AE1A97E2EA4E1EEBB16B18DCEA0AED5 https://www.tecartushcp.com/-/media/tecartushcp/icon--all-factor--gray-status.ashx?iar=0&hash=0DB6181F1D771FF230739A6AFC35D68E https://www.tecartushcp.com/-/media/tecartushcp/icon--all-factor--gray-status-mobile.ashx?iar=0&hash=CDCA4834CF645C4660FB7420898D98B6 https://www.tecartushcp.com/-/media/tecartushcp/icon--all-factor--gray-relapse.ashx?iar=0&hash=EF60D5BFEC0EC24CD1418B2818A3D4CB https://www.tecartushcp.com/-/media/tecartushcp/icon--all-factor--gray-relapse-mobile.ashx?iar=0&hash=36806666AE62209D2C62CB7DA0EDF2EA https://www.tecartushcp.com/car-t-cell-therapy/mantle-cell-lymphoma/unmet-need 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/chart--unmet-response-rates--large.ashx?h=292&iar=0&w=983&hash=262EAD4574CDF2D311E92A8152E12FB6 https://www.tecartushcp.com/-/media/tecartushcp/chart--unmet-response-rates--small.ashx?h=415&iar=0&w=269&hash=5DD5C553A99CF84A409481E5DF9B1872 https://www.tecartushcp.com/-/media/tecartushcp/chart--unmet-survival-rates--large.ashx?h=213&iar=0&w=983&hash=422A2712E91334D13732639003E7E93D https://www.tecartushcp.com/-/media/tecartushcp/chart--unmet-survival-rates--small.ashx?h=382&iar=0&w=270&hash=789C258E8BE81A1DA26AC9810032D1AF https://www.tecartushcp.com/car-t-cell-therapy/acute-lymphoblastic-leukemia/design-and-manufacturing 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/image--binding-mechanism--color.ashx?iar=0&hash=D136B9A0A708D56EC3C4F00C398A5DED https://www.tecartushcp.com/-/media/tecartushcp/image--binding-mechanism--color-m.ashx?iar=0&hash=B67F798DEB6E474373519FA9DAACD3E5 https://www.tecartushcp.com/-/media/tecartushcp/image--all-d-n-m-cell1.ashx?iar=0&hash=8F29B36059EC691456BB938D309F4435 https://www.tecartushcp.com/-/media/tecartushcp/image--all-d-n-m-cell2.ashx?iar=0&hash=B9178395FAD7E0018775C736738D6FB7 https://www.tecartushcp.com/-/media/tecartushcp/predictability-reliability-flexibility-d-all.ashx?iar=0&hash=9DC0E9297E6BDA0E311001C5F323E371 https://www.tecartushcp.com/-/media/tecartushcp/predictability-reliability-flexibility-m-all.ashx?iar=0&hash=2227726F56DD73DC6180B9ED3E539E9F https://www.tecartushcp.com/car-t-cell-therapy/acute-lymphoblastic-leukemia/treatment 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/graphic--all--treatment-process--large.ashx?h=888&iar=0&w=920&hash=E2ABBBF1A384E2D1DD15CDC007054B77 https://www.tecartushcp.com/-/media/tecartushcp/graphic--all--treatment-process--small.ashx?h=1478&iar=0&w=316&hash=4A6D5FB2A57D92B8D9B8C53B2770C6B1 https://www.tecartushcp.com/car-t-cell-therapy/mantle-cell-lymphoma/zuma-2-trial-study-design 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/pivotal-study-d.ashx?iar=0&hash=F67C7F8F48F5E56CC3F1D1432D233358 https://www.tecartushcp.com/-/media/tecartushcp/pivotal-study-design-m.ashx?iar=0&hash=CB4F10127ABFE9661B30FEC811D0E56A https://www.tecartushcp.com/-/media/tecartushcp/patient-characteristics-d.ashx?iar=0&hash=726D907107A78EA16718228E8D955BAC https://www.tecartushcp.com/-/media/tecartushcp/patient-characteristics-m.ashx?iar=0&hash=48B65075276D826FC5727C664AFB5967 https://www.tecartushcp.com/car-t-cell-therapy/acute-lymphoblastic-leukemia/response 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/chart--response-orr--large--all.png?h=734&iar=0&w=1410&hash=CE8ADC848F794D423378AF8F8C690150 https://www.tecartushcp.com/-/media/tecartushcp/chart--response-orr--small--all.png?h=294&iar=0&w=560&hash=65AFD86DF07B16B775CEDC63A7055602 https://www.tecartushcp.com/-/media/tecartushcp/chart--response-dor--large--all-1.ashx?iar=0&hash=49EF047A264189CAC0EDEF7CE6BCB188 https://www.tecartushcp.com/-/media/tecartushcp/chart--response-dor--small--all-1.ashx?iar=0&hash=F1AE37BFB8C5B132694EB0E79B55D3E3 https://www.tecartushcp.com/-/media/tecartushcp/chart--response-dor--large--all-2.ashx?iar=0&hash=7D65AA962BA3C39F2C84E7739B3B0729 https://www.tecartushcp.com/-/media/tecartushcp/chart--response-dor--small--all-2.ashx?iar=0&hash=FC681589FFBD74165C5A3F787EE66018 https://www.tecartushcp.com/car-t-cell-therapy/mantle-cell-lymphoma/kite-konnect 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/kk_find-a-treatment-center_icon.ashx https://www.tecartushcp.com/-/media/tecartushcp/kk_logistics-support_icon.ashx https://www.tecartushcp.com/-/media/tecartushcp/kk_reimbursement-support_icon.ashx https://www.tecartushcp.com/-/media/tecartushcp/kk_enroll-a-patient_icon.ashx https://www.tecartushcp.com/-/media/tecartushcp/kk_ongoing-commitment_icon.ashx https://www.tecartushcp.com/-/media/tecartushcp/logo--kite-color.ashx https://www.tecartushcp.com/car-t-cell-therapy/acute-lymphoblastic-leukemia/unmet-need 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/chart--unmet-os-rates--large--all.ashx?h=503&iar=0&w=980&hash=5AAD8282C6621405A113A5111328BE0D https://www.tecartushcp.com/-/media/tecartushcp/chart--unmet-os-rates--small--all.ashx?h=546&iar=0&w=798&hash=9280A4E2AA2430CEEA270AEF851A7610 https://www.tecartushcp.com/-/media/tecartushcp/table--unmet-patient-type--large.ashx?h=292&iar=0&w=982&hash=67181E63AB806009C30F7E1E985DD965 https://www.tecartushcp.com/-/media/tecartushcp/table--unmet-patient-type--small.ashx?h=978&iar=0&w=804&hash=420646A3D10867090AD14985C0411E17 https://www.tecartushcp.com/-/media/tecartushcp/chart--unmet-survival-rates--large--all.ashx?h=445&iar=0&w=980&hash=2A2C38EDA63537F3C30ADA54B3BECA90 https://www.tecartushcp.com/-/media/tecartushcp/chart--unmet-survival-rates--small--all.ashx?h=1419&iar=0&w=798&hash=E8D56D40E3B55D3C54C2A07BDDFF2550 https://www.tecartushcp.com/car-t-cell-therapy/acute-lymphoblastic-leukemia/treatment-center-locator 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/icon--treatment-center--gradient-424.ashx?iar=0&hash=4C7A7FB23448BEBEE1D282D0E960D5FD https://www.tecartushcp.com/car-t-cell-therapy/acute-lymphoblastic-leukemia/-/media/tecartushcp/logo-kite.png https://www.tecartushcp.com/car-t-cell-therapy/mantle-cell-lymphoma/treatment-center-locator 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/icon--treatment-center--gradient-424.ashx?iar=0&hash=4C7A7FB23448BEBEE1D282D0E960D5FD https://www.tecartushcp.com/car-t-cell-therapy/mantle-cell-lymphoma/-/media/tecartushcp/logo-kite.png https://www.tecartushcp.com/car-t-cell-therapy/mantle-cell-lymphoma/adverse-events 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/cartard.ashx?iar=0&hash=F508DDCA8C5CF1F79479DBC69B3E1C98 https://www.tecartushcp.com/-/media/tecartushcp/cartarm.ashx?iar=0&hash=E1DABC3FE556F1FE9B435FA8B4124224 https://www.tecartushcp.com/tecartushcp/tecartushcp.com/Content/svg/icon--long-arrow--gray.svg https://www.tecartushcp.com/tecartushcp/tecartushcp.com/Content/svg/icon--long-arrow--gray--mobile.svg https://www.tecartushcp.com/-/media/tecartushcp/icon--zuma-2-onsite-monitoring.ashx?iar=0&hash=E0CE61E58D07E918C7DCA758F769889B https://www.tecartushcp.com/-/media/tecartushcp/icon--zuma-2-post-discharge.ashx?iar=0&hash=F211F684821FF5D53144B8CC10E586F0 https://www.tecartushcp.com/-/media/tecartushcp/icon--zuma-2-long-term.ashx?iar=0&hash=DC4882FF9CF27AB039F7D1AEE7383763 https://www.tecartushcp.com/-/media/tecartushcp/icon--vials--color.ashx?h=82&iar=0&w=80&hash=E0E6AE2D8C8E6062202B853AEA95FE33 https://www.tecartushcp.com/-/media/tecartushcp/icon--vials--color-mobile.ashx?iar=0&hash=B0969E098068CB43A89A66B8CCE16AFC https://www.tecartushcp.com/-/media/tecartushcp/icon--phone--color.ashx?iar=0&hash=62C3E5DC684BB4484428C23B1A52F1C7 https://www.tecartushcp.com/-/media/tecartushcp/icon--phone--color-mobile.ashx?iar=0&hash=B369E6C63F240B4985676314124AB3A7 https://www.tecartushcp.com/car-t-cell-therapy/acute-lymphoblastic-leukemia/zuma-3-trial-study-design 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/graphic--zuma3-study--large--all.ashx?h=263&iar=0&w=981&hash=B71784CF2F8ED024CFCBF25411A99D7D https://www.tecartushcp.com/-/media/tecartushcp/graphic--zuma3-study--small--all.ashx?h=373&iar=0&w=268&hash=DE760A503176663F36889D76A3F022E1 https://www.tecartushcp.com/-/media/tecartushcp/table--zuma-patient-baseline--large--all.ashx?h=600&iar=0&w=982&hash=440B9BBA544ED7E2F8A572A34E635142 https://www.tecartushcp.com/-/media/tecartushcp/table--zuma-patient-baseline--small--all.ashx?iar=0&hash=EB178F3C374C4A3EFA4857B8FF96967C https://www.tecartushcp.com/car-t-cell-therapy/acute-lymphoblastic-leukemia/adverse-events 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/table--adverse-events--large--all.ashx?iar=0&hash=43D9BCF650D96A92FD418BFD1FEE5EA5 https://www.tecartushcp.com/-/media/tecartushcp/table--adverse-events--small--all.ashx?iar=0&hash=700956AB43D70AFD9A4958FA7BA4358C https://www.tecartushcp.com/-/media/tecartushcp/icon--vials--color.ashx?h=82&iar=0&w=80&hash=E0E6AE2D8C8E6062202B853AEA95FE33 https://www.tecartushcp.com/-/media/tecartushcp/icon--vials--color-mobile.ashx?iar=0&hash=B0969E098068CB43A89A66B8CCE16AFC https://www.tecartushcp.com/-/media/tecartushcp/icon--calendar--color.ashx?iar=0&hash=F768C67685617C7B5FE4470985B35A26 https://www.tecartushcp.com/-/media/tecartushcp/icon--treatment-center--gradient.ashx?iar=0&hash=40F01E0F7CBECBBF645BF2F3AFDAA4E2 https://www.tecartushcp.com/-/media/tecartushcp/icon--treatment-center--gradient--small.ashx?iar=0&hash=1FC93E71DB7B148390825B425221CEAA https://www.tecartushcp.com/-/media/tecartushcp/icon--phone--color.ashx?iar=0&hash=62C3E5DC684BB4484428C23B1A52F1C7 https://www.tecartushcp.com/-/media/tecartushcp/icon--phone--color-mobile.ashx?iar=0&hash=B369E6C63F240B4985676314124AB3A7 https://www.tecartushcp.com/car-t-cell-therapy/acute-lymphoblastic-leukemia/kite-konnect 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/kk_find-a-treatment-center_icon.ashx https://www.tecartushcp.com/-/media/tecartushcp/kk_logistics-support_icon.ashx https://www.tecartushcp.com/-/media/tecartushcp/kk_reimbursement-support_icon.ashx https://www.tecartushcp.com/-/media/tecartushcp/kk_enroll-a-patient_icon.ashx https://www.tecartushcp.com/-/media/tecartushcp/kk_ongoing-commitment_icon.ashx https://www.tecartushcp.com/-/media/tecartushcp/logo--kite-color.ashx https://www.tecartushcp.com/car-t-cell-therapy/acute-lymphoblastic-leukemia/safety-profile 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/table--adverse-reactions--large--all.ashx?h=1306&iar=0&w=733&hash=7BA4A426ED58400E9459EAC471801312 https://www.tecartushcp.com/-/media/tecartushcp/table--adverse-reactions--small--all.ashx?h=1697&iar=0&w=266&hash=6AE330425C60C76F1EB4887E69F05D52 https://www.tecartushcp.com/-/media/tecartushcp/table--lab-abnormalities--large--all.ashx?iar=0&hash=223A0F85C8214271A63F1A42429E0B74 https://www.tecartushcp.com/-/media/tecartushcp/table--lab-abnormalities--small--all.ashx?iar=0&hash=E0C567AC90A04A3ED7CF2BC4901DE1BF https://www.tecartushcp.com/car-t-cell-therapy/acute-lymphoblastic-leukemia/additional-efficacy-data 2023-12-21 monthly 0.8 https://www.tecartushcp.com/-/media/tecartushcp/branded-chart-rfs.ashx?iar=0&hash=DD82335249F2DD8D655F86CE9B065854 https://www.tecartushcp.com/-/media/tecartushcp/branded-chart-rfs-m.ashx?h=194&iar=0&w=266&hash=ACC5CE91495E366DAD71E67BCC7E5EF0 https://www.tecartushcp.com/-/media/tecartushcp/m-rfs-3-yr-zuma-d-all.ashx?iar=0&hash=6F9484F2A48AB1FCC00FF6D26A0B2D43 https://www.tecartushcp.com/-/media/tecartushcp/m-rfs-3-yr-zuma-m-all.ashx?h=573&iar=0&w=798&hash=B5A8AFDD9E0A0D22ABF6FD8929B7734A